Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial CNBCNovo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial ReutersNovo Nordisk Stock Plunges and Eli Lilly Jumps. It's Because of This Weight-Loss Drug Trial. Barron'sNovo Nordisk Trial Flop Ripples Through Denmark's Stock Market Bloomberg
Korean ‘ants' pile into leveraged funds to profit from stock market boom Financial TimesHow Korea's President Turned Its Market Into the World's Best Performer Bloomberg.comShould You Bet on South Korea ETFs After the Kospi Rally? Yahoo FinanceSouth Korea's Kospi jumps to record high as regional rally tracks Wall Street gains CNBC
Defense attorneys build mapping tool to track Justice Dept. "weaponization" CBS NewsDoJ cases against protesters keep collapsing as officers' lies are exposed in court The GuardianThe Justice Department is not acting like it used to, criminal defense lawyers note NPRWar declared on Trump DOJ's 'abnormal' behavior by fed-up attorneys rawstory.com
Netflix Officially Under DOJ Antitrust Scrutiny "To Create A Monopoly" With Warner Bros Merger; Feds Want Details From Producers & Filmmakers On Streamer's Leverage DeadlineHollywood merger threatens movie theaters just as they recover The Boston GlobeDOJ Probes Netflix's Power Over Filmmakers in Warner Deal Review BloombergMark Ruffalo Fires Back at James Cameron After ‘Avatar' Director Slammed Netflix-Warner Bros. Deal: ‘Are You Also Against the Monopolization That a Paramount Acquisition Would Create?' Variety
